Patients at the center of digital transformation in Lundbeck China

Our affiliate in China has launched a new digital Patient Care Solution program. Rooted in our patient-centricity belief, the program strives to address the challenge of treatment access and other major pain points Chinese patients and healthcare professionals (HCPs) face.

This is Lundbeck

We are one of the only pharmaceutical companies in the world focusing exclusively on brain diseases, and we’re set apart by our specialization.

About Us

With more than 70 years of neuroscience expertise, Lundbeck has developed and commercialized some of the world's most widely prescribed therapies for brain diseases.

Our Science

LATEST NEWS

17 June, 2022 Press Release
European Medicines Agency Commences Review of Aripiprazole 2-Month Long-Acting Injectable for the Maintenance Treatment of Schizophrenia in Adult Patients Stabilised with Aripiprazole
16 June, 2022 Press Release
Results from the DELIVER study with Vyepti® has been published in a top-ranking medical journal
09 June, 2022 Feature
Patients at the center of digital transformation in Lundbeck China

See All News

Come join us in making a difference to patients worldwide.

Job Opportunities

Explore the latest financial developments at Lundbeck.

Investors

a better life for people with brain diseases

At Lundbeck, we see patients as people and are committed to support the person behind the disease.

Patients

Partnering

The complexity of brain diseases requires a concerted effort. We are committed to develop new and better treatment options from innovations born in house or externally.

jason F. houston on working at Lundbeck

Advocacy Makes the Difference

See All Stories

Lundbeck at a glance

100

countries where our products are sold

5,300

employees supporting our purpose

1915

year Lundbeck was founded

No Health Without Mental Health

A Strange Dream

Out of the Silence: Speaking Up About Migraine

A messenger of hope